Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000041550
Ethics application status
Approved
Date submitted
13/11/2023
Date registered
17/01/2024
Date last updated
17/01/2024
Date data sharing statement initially provided
17/01/2024
Type of registration
Retrospectively registered
Titles & IDs
Public title
Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)
Query!
Scientific title
Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)
Query!
Secondary ID [1]
310948
0
Nil Known
Query!
Universal Trial Number (UTN)
U1111-1300-3340
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Post Traumatic Stress Disorder (PTSD)
332025
0
Query!
Condition category
Condition code
Mental Health
328756
328756
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
MDMA medicines are given orally in a capsule form once in the morning on the medicine days only. The medicine dosing is by the treating psychiatrist, and he will ensure the patient has swallowed the medicine at dosing. No other strategies are available or indicated. The medicines used are Methylenedioxy methamphetamine (MDMA) for PTSD.
Medicine days occur 2-3 times (depending on response to treatment) interspersed with psychotherapy for all arms of treatment:
ie for all arms: 3 Preparatory sessions/1 Medicine Day/3 Integration Sessions 1 week apart/ 1 Medicine Day/ 3 Integration Sessions 1 week apart/ Then an optional 3rd Medicine Day and 3 Integration Sessions 1 week apart, if there's an inadequate response to treatment
The usual dose of MDMA for arms 1 and 2, will be 120mg with 60mg top up 2 hours later as per the MAPS studies. The 80mg with 40mg top up will be if the higher dose option is not tolerated. If the patient is quite anxious we may dose the first medicine day at 80mg plus 40mg top up. Then move to 120mg plus 60mg top up for subsequent sessions.
Arm 1 active : MDMA (80-120mg + 40-60mg top up) given once in morning on 2-3 medicine days only through the treatment interspersed with usual supportive psychotherapy (as detailed below).
Arm 2 active : MDMA (80-120mg + 40-60mg) given once in morning on 2-3 medicine days through the treatment interspersed with psychotherapy where 1 of each of the 3 Integration Sessions is a specialised EMDR (eye movement desesitisation and reprocessing) session; with the other 2 sessions being usual supportive psychotherapy
Psychotherapy (all sessions are 1 hour)
• Three preparation sessions held approximately a week apart.
Dr Ranil Gunewardene will conduct the first preparation session 1:1 in rooms or via Zoom for 60 minutes. During this session, further in depth assessment will take place and medical review.
The second and third preparation session will be with a HREC approved Psychologist/ psychotherapist 1:1 either in rooms or via Zoom for 1 hour each.
• One Dosing session ( approximately 6-7 hours face to face) where supportive, client centered psychotherapy is provided during the dosing experience at Northern Beaches Hospital Clinic Rooms. Psychiatrist Dr Ranil Gunewardene will conduct the administration of medicine, regular monitoring and medical supervision of the client. Dr Ranil Gunewardene will provide direct client time face to face as clinically required. The designated treating HREC approved Psychologist/ Psychotherapist will work face to face with the client throughout their dosing day providing client centered psychotherapy.
• Three Integration sessions conducted 1:1 by HREC approved the psychologist/ psychotherapist with the first one held the day after the dosing session and then held approximately a week apart.
• In Arm 2 one of the 3 Integration Sessions will be EMDR. All other psychotherapy sessions, including all sessions for Arms 1, will be as detailed as per the supportive model below
Who:
HREC approved Psychologists/Psychotherapists conducting the preparation sessions, dosing and integration therapy sessions are all fully registered and have additional training in psychedelic assisted therapy.
Mode of Administration:
Preparation and Integration sessions will be 1:1 with a psychologist/ psychotherapist or psychiatrist and will be offered either face to face or via Zoom for 60 minutes.
Monitoring:
• The treatment dyad consisting of Dr Ranil Gunewardene and one of the HREC approved PAT trained psychologists/psychotherapists will be consistent across the course of the treatment and will ensure follow up any non attendance at appointments with telephone contact from the clinic to support adherence to the full therapy program.
• A spreadsheet that records client dates of sessions and disengagement from the therapy program prior to completion will be recorded along with action taken to re-engage the client.
• Adverse Events will be recorded and reported to HREC and TGA
• Pre and post psychometric measures will be administered.
Psychedelic Assisted Psychotherapy for both MDMA and Psilocybin is taught during Psychedelic Assisted Therapy training programs that have been completed by all of the psychologists/psychotherapists and the psychiatrist delivering the service.
In Summary the therapy approach for all sessions is simply supportive psychotherapy based. There is psychoeducation delivered and set setting and relationship building is undertaken. The therapist is encouraged to stay out of the way of the patient’s medicine guided realisations and perspective shifts. To be guided by the patient’s experiences not the therapist’s agenda. To encourage the rediscovering of the wiser self and to promote patient agency. The therapist is there to support the patient rediscovering and connecting to their “inner healing intelligence”. There are principles of emotional support, encouragement, validation of experiences and perspectives, exploration of feeling states, in a non directive and non judgmental therapist stance.
EMDR as one of the Integration Sessions in Arm 2
The two EMDR sessions will be delivered as one of the group of 3 post dosing integration sessions in Arm 2 only. Ie 1 EMDR session per block of 3 integration sessions.
The EMDR sessions will be held 1:1 in face to face 60 minute sessions. All psychologists/ psychotherapists have been trained in EMDR and are experienced with this treatment model.
The first EMDR session involves a brief explanation of EMDR treatment model and methods. The therapist then identifies the target memory or experience that is central to the trauma. The associated image, negative cognition, body sensation and emotion are then identified and the client provides a subjective rating of distress out of 10. Multiple sets of Bilateral Stimulation (usually eye movement where the client tracks the hand movement of the therapist) that last 30 -120 seconds, with breaks for brief check in and minimal prompts by the therapist if required. The distress rating is reviewed and if it is zero on three occasions, then a positive cognition is installed using further Bilateral Stimulation. The session is then reviewed and concludes.
The second session will begin with a review of the previous session and client experience in between sessions. The target memory is reviewed with the associated image, negative cognition, body sensation and emotion and the level of distress rated out of 10. Further BLS is conducted and the distress rating is reviewed and if it is zero on three occasions, then a positive cognition is installed using further Bilateral Stimulation.
Query!
Intervention code [1]
327380
0
Treatment: Drugs
Query!
Intervention code [2]
327381
0
Treatment: Other
Query!
Comparator / control treatment
MDMA medicines are given orally in a capsule form once in the morning on the medicine days only. The medicine dosing is by the treating psychiatrist, and he will ensure the patient has swallowed the medicine at dosing. No other strategies are available or indicated. The medicines used are Methylenedioxy methamphetamine (MDMA) for PTSD.
Medicine days occur 2-3 times (depending on response to treatment) interspersed with psychotherapy for all arms of treatment:
ie for all arms: 3 Preparatory sessions/1 Medicine Day/3 Integration Sessions 1 week apart/ 1 Medicine Day/ 3 Integration Sessions 1 week apart/ Then an optional 3rd Medicine Day and 3 Integration Sessions 1 week apart, if there's an inadequate response to treatment
The usual dose of MDMA for arms 1 and 2, will be 120mg with 60mg top up 2 hours later as per the MAPS studies. The 80mg with 40mg top up will be if the higher dose option is not tolerated. If the patient is quite anxious we may dose the first medicine day at 80mg plus 40mg top up. Then move to 120mg plus 60mg top up for subsequent sessions.
Arm 1 active : MDMA (80-120mg + 40-60mg top up) given once in morning on 2-3 medicine days only through the treatment interspersed with usual supportive psychotherapy (as detailed below).
Psychotherapy (all sessions are 1 hour)
• Three preparation sessions held approximately a week apart.
Dr Ranil Gunewardene will conduct the first preparation session 1:1 in rooms or via Zoom for 60 minutes. During this session, further in depth assessment will take place and medical review.
The second and third preparation session will be with a HREC approved Psychologist/ psychotherapist 1:1 either in rooms or via Zoom for 1 hour each.
• One Dosing session ( approximately 6-7 hours face to face) where supportive, client centered psychotherapy is provided during the dosing experience at Northern Beaches Hospital Clinic Rooms. Psychiatrist Dr Ranil Gunewardene will conduct the administration of medicine, regular monitoring and medical supervision of the client. Dr Ranil Gunewardene will provide direct client time face to face as clinically required. The designated treating HREC approved Psychologist/ Psychotherapist will work face to face with the client throughout their dosing day providing client centered psychotherapy.
• Three Integration sessions conducted 1:1 by HREC approved the psychologist/ psychotherapist with the first one held the day after the dosing session and then held approximately a week apart.
Who:
HREC approved Psychologists/Psychotherapists conducting the preparation sessions, dosing and integration therapy sessions are all fully registered and have additional training in psychedelic assisted therapy.
Mode of Administration:
Preparation and Integration sessions will be 1:1 with a psychologist/ psychotherapist or psychiatrist and will be offered either face to face or via Zoom for 60 minutes.
Monitoring:
• The treatment dyad consisting of Dr Ranil Gunewardene and one of the HREC approved PAT trained psychologists/psychotherapists will be consistent across the course of the treatment and will ensure follow up any non attendance at appointments with telephone contact from the clinic to support adherence to the full therapy program.
• A spreadsheet that records client dates of sessions and disengagement from the therapy program prior to completion will be recorded along with action taken to re-engage the client.
• Adverse Events will be recorded and reported to HREC and TGA
• Pre and post psychometric measures will be administered.
Psychedelic Assisted Psychotherapy for both MDMA and Psilocybin is taught during Psychedelic Assisted Therapy training programs that have been completed by all of the psychologists/psychotherapists and the psychiatrist delivering the service.
In Summary the therapy approach for all sessions is simply supportive psychotherapy based. There is psychoeducation delivered and set setting and relationship building is undertaken. The therapist is encouraged to stay out of the way of the patient’s medicine guided realisations and perspective shifts. To be guided by the patient’s experiences not the therapist’s agenda. To encourage the rediscovering of the wiser self and to promote patient agency. The therapist is there to support the patient rediscovering and connecting to their “inner healing intelligence”. There are principles of emotional support, encouragement, validation of experiences and perspectives, exploration of feeling states, in a non directive and non judgmental therapist stance.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
336811
0
Change in clinican rated PTSD symptoms from baseline
Query!
Assessment method [1]
336811
0
Change in Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS 5) from baseline
Query!
Timepoint [1]
336811
0
Baseline and 2 weeks after treatment completed
Query!
Secondary outcome [1]
428824
0
Change in PTSD symptoms from baseline
Query!
Assessment method [1]
428824
0
Change in PTSD Checklist for DSM V (PCL-5) from baseline
Query!
Timepoint [1]
428824
0
At baseline and 2 weeks after therapy completed
Query!
Secondary outcome [2]
429343
0
Change in trauma from baseline
Query!
Assessment method [2]
429343
0
Change in International Trauma Questionnaire (ITQ) from baseline
Query!
Timepoint [2]
429343
0
At baseline and 2 weeks after therapy completed
Query!
Secondary outcome [3]
429734
0
Change in adverse events from baseline
Query!
Assessment method [3]
429734
0
Change in Adverse Childhood Experiences Assessment (ACE) from baseline
Query!
Timepoint [3]
429734
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [4]
429735
0
Change in personality disorder symptoms from baseline
Query!
Assessment method [4]
429735
0
Change in MacLean Screening Instrument for BPD (MSI) from baseline
Query!
Timepoint [4]
429735
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [5]
429736
0
Change in disability
Query!
Assessment method [5]
429736
0
Change in World Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0) from baseline
Query!
Timepoint [5]
429736
0
baseline and 2 weeks post treatment
Query!
Secondary outcome [6]
429737
0
Change in connection from baseline
Query!
Assessment method [6]
429737
0
Change in Watts Connectedness Scale (WCS) from baseline
Query!
Timepoint [6]
429737
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [7]
429738
0
Change in relationships from baseline
Query!
Assessment method [7]
429738
0
Change in Quality of Relationships Inventory (QRI) from baseline
Query!
Timepoint [7]
429738
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [8]
430200
0
Change in mystical experiences from baseline
Query!
Assessment method [8]
430200
0
Change in Revised Mystical Experiences Questionnaire (MEQ-30) from baseline
Query!
Timepoint [8]
430200
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [9]
430201
0
Change in alcohol use from baseline
Query!
Assessment method [9]
430201
0
Change in Alcohol Use Disorders Identification Test (AUDIT) from baseline
Query!
Timepoint [9]
430201
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [10]
430202
0
Change in drug use from baseline
Query!
Assessment method [10]
430202
0
Change in Drug Use Identification Test (DUDIT) from baseline
Query!
Timepoint [10]
430202
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [11]
430203
0
Change in suicidal ideation from baseline
Query!
Assessment method [11]
430203
0
Change in Columbia Suicide Severity Rating Scale (CSSR-S) from baseline
Query!
Timepoint [11]
430203
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [12]
430204
0
Change in clinician rated depression from baseline
Query!
Assessment method [12]
430204
0
Change in Montgomery-Asberg Depression Scale (MADRS) from baseline
Query!
Timepoint [12]
430204
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [13]
430205
0
Change in depression
Query!
Assessment method [13]
430205
0
Change in Depression Anxiety Stress Scale (DASS) from baseline
Query!
Timepoint [13]
430205
0
Baseline and 2 weeks post treatment
Query!
Secondary outcome [14]
430779
0
Change in eating attitudes from baseline [Substudy for patients with symptoms of an eating disorder]
Query!
Assessment method [14]
430779
0
Change in Eating Disorder Questionnaire-15 scores from baseline
Query!
Timepoint [14]
430779
0
baseline and 2 weeks post treatment
Query!
Secondary outcome [15]
430780
0
Change in disordered eating from baseline [Substudy for patients with symptoms of an eating disorder]
Query!
Assessment method [15]
430780
0
Change in Eating Disorder Examination Questionnaire scores from baseline
Query!
Timepoint [15]
430780
0
baseline and 2 weeks post treatment
Query!
Secondary outcome [16]
430781
0
Change in eating disorder symptomology from baseline [Substudy for patients with symptoms of an eating disorder]
Query!
Assessment method [16]
430781
0
Change in Eating Disorder Inventory-3 from baseline
Query!
Timepoint [16]
430781
0
baseline and 2 weeks post treatment
Query!
Eligibility
Key inclusion criteria
Must suffer from: Post Traumatic Stress Disorder
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
(1) Is not able to give adequate informed consent, or is under 18 or over 65 years old.
(2) Has uncontrolled hypertension or unstable diabetes.
(3) Has a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] corrected by Bazett's formula)1
(4) Has a history of additional risk factors for Torsade de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome).
(5) Has evidence or history of significant medical disorders e.g. epilepsy, stroke, unstable cardio vascular disease
(6) Has symptomatic liver disease.
(7) Has a history of hyponatremia or hyperthermia.
(8) Weighs less than 48 kg.
(9) Is pregnant or nursing or is of childbearing age and is not practicing an effective means of birth control.
10) Is currently abusing illegal drugs
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
We will use and online randomiser to fairly allocate patients to one of 2 active arms: 1) Control: MDMA with usual supportive psychotherapy only 2) MDMA with mainly supportive psychotherapy but where 1 of the 3 integration session groups is an EMDR session. The rest of the sessions are supportive only
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
online computer generated randomiser
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/12/2023
Query!
Date of last participant enrolment
Anticipated
18/12/2028
Query!
Actual
Query!
Date of last data collection
Anticipated
5/01/2029
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
2
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Funding & Sponsors
Funding source category [1]
315208
0
Self funded/Unfunded
Query!
Name [1]
315208
0
Patients are self funded or may be funded by an organisation eg an Insurance company Armed Forces Department of Veterans Affairs etc
Query!
Address [1]
315208
0
Query!
Country [1]
315208
0
Query!
Primary sponsor type
Individual
Query!
Name
Dr and A/ Professor Ranil Gunewardene
Query!
Address
Northern Beaches Hospital Mindlife Clinic Suite 18 Level 7, 105 Frenchs Forest Rd West Frenchs Forest NSW 2086
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317241
0
None
Query!
Name [1]
317241
0
Query!
Address [1]
317241
0
Query!
Country [1]
317241
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314133
0
Townsville Hospital and Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
314133
0
100 Angus Smith Drive Douglas QLD 4814
Query!
Ethics committee country [1]
314133
0
Australia
Query!
Date submitted for ethics approval [1]
314133
0
16/10/2023
Query!
Approval date [1]
314133
0
08/11/2023
Query!
Ethics approval number [1]
314133
0
HREC/2023/QTHS/103245
Query!
Summary
Brief summary
We intend to measure the effectiveness of psychedelic assisted medicines (methylene dioxy methamphetamine - MDMA) when combined with talking therapy; for the treatment of Post Traumatic Stress Disorder in real world patient groups
We will test how effective MDMA is for PTSD and treat patients who have had limited benefits with existing treatments for these hard to treat conditions.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
130530
0
A/Prof Dr Ranil Gunewardene
Query!
Address
130530
0
Mindlife Clinic Northern Beaches Hospital Suite 18, Level 7, 105 Frenchs Forest Rd West Frenchs Forest NSW 2086
Query!
Country
130530
0
Australia
Query!
Phone
130530
0
+61 0466534211
Query!
Fax
130530
0
Query!
Email
130530
0
[email protected]
Query!
Contact person for public queries
Name
130531
0
Ms Kitrina Heathcoate
Query!
Address
130531
0
Mindlife Clinic Northern Beaches Hospital Suite 18, Level 7, 105 Frenchs Forest Rd West Frenchs Forest NSW 2086
Query!
Country
130531
0
Australia
Query!
Phone
130531
0
+61 0424292306
Query!
Fax
130531
0
Query!
Email
130531
0
[email protected]
Query!
Contact person for scientific queries
Name
130532
0
Dr Ranil Gunewardene
Query!
Address
130532
0
Mindlife Clinic Northern Beaches Hospital Suite 18, Level 7, 105 Frenchs Forest Rd West Frenchs Forest NSW 2086
Query!
Country
130532
0
Australia
Query!
Phone
130532
0
+61 0466534211
Query!
Fax
130532
0
Query!
Email
130532
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Data is grouped into assessment scale scores for all patients
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF